Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T25537 Target Info
Target Name Mitogen-activated protein kinase (MAPK)
Synonyms MAPK; Extracellular signal-regulated kinase; ERK
Target Type Clinical trial Target
Gene Name NO-GeName
Biochemical Class Kinase
UniProt ID
NOUNIPROTAC
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2011151358
Title 2 -Amino- Pyrimidine Derivatives Useful As Inhibitors of Jnk.
Abstract Compounds of formula I or pharmaceutically acceptable salts thereof, wherein R5 is a group of formula (a) or (b): and wherein m, n, p, q, X, Y, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity.
Applicant(s) F. Hoffmann-La Roche Ag
Representative Drug(s) D0J8PJ Drug Info IC50 = 46 nM Click to Show More [1]
2 D0CS9R Drug Info IC50 = 71 nM [1]
3 D0Y4KU Drug Info IC50 = 80 nM [1]
Patent ID WO2011151357
Title Inhibitors of Jnk.
Abstract Compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein: wherein m, n, p, q, X Y, Z, A, R1, R2, R3, R4, R5 and Y6 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity.
Applicant(s) F. Hoffmann-La Roche Ag
Representative Drug(s) D01FTR Drug Info IC50 = 31 nM Click to Show More [1]
2 D0QK6D Drug Info IC50 = 135 nM [1]
Patent ID WO2012083092
Title Bi-Dentate Compounds As Kinase Inhibitors.
Abstract The present disclosure provides compound having the general structure A or pharmaceutically acceptable salts thereof: Het-L-P (A) wherein Het is an aromatic moiety comprising a heterocyclic structure mimicking ATP, P is a docking site derived peptide or a docking site peptide rnimetic, and L is a linking moiety, wherein L links the ATP mimetic to the docking site peptide moiety. The compounds having the general structure A can serve as inhibitors of kinases, such as the kinases JNK, Erk and p38.
Applicant(s) Sanford-Burnham Medical Research Institute
Representative Drug(s) D08OJQ Drug Info IC50 = 0.3 nM Click to Show More [1]
2 D0G7LB Drug Info IC50 = 18 nM [1]
3 D09EWC Drug Info N.A. [1]
Patent ID WO2013074986
Title Inhibitors of C-Jun-N-Terminal Kinase (Jnk).
Abstract The present invention provides novel compounds according to Formula (I): where Ring A, Ring B, X, L1, L2, RA, RC, RD, RE, m, n, and p are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of human diseases associated with kinase activity, for example, proliferative diseases, neurodegenerative diseases, metabolic disorders, inflammatory diseases, and cardiovascular diseases.
Applicant(s) Dana-Farber Cancer Institute, Inc
Representative Drug(s) D04JVY Drug Info IC50 = nM range Click to Show More [1]
2 D0PG5N Drug Info N.A. [1]
Patent ID WO2014170706
Title Galloyl Benzamide-Based Compounds As Jnk Modulators.
Abstract The present invention relates to the use of compounds having a galloyl benzamide structure in the treatment and/or prevention of medical conditions mediated through c-Jun N-terminal kinases (JNKs) and to pharmaceutical compositions comprising said compounds.
Applicant(s) Universit Degli Studi Di Bari
Representative Drug(s) D0O2EF Drug Info N.A. Click to Show More [1]
2 D0V7UQ Drug Info N.A. [1]
Patent ID WO2010091310
Title Inhibitors of Jun N-Terminal Kinase.
Abstract The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
Applicant(s) Elan Pharmaceuticals, Inc
Representative Drug(s) D0GX7W Drug Info N.A. Click to Show More [1]
2 D0UY9Y Drug Info N.A. [1]
Patent ID WO2011071491
Title Isotopologues of 4-[9-(Tetrahydro-Furan-3-Yl)-8-(2, 4, 6- Trifluoro-Phenylamino)-9H-Purin-2-Ylamino]-Cyclohexan-1-Ol.
Abstract Provided herein are isotopologues of Compound 1, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.
Applicant(s) Signal Pharmaceuticals
Representative Drug(s) D0W7MG Drug Info N.A. [1]
Patent ID WO2010108155
Title Modulators of Cystic Fibrosis Transmembrane Conductance Regulator.
Abstract This invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R is COOH or CH2OH.
Applicant(s) Vertex Pharmaceuticals Incorporated
Representative Drug(s) D0X7OF Drug Info N.A. [1]
References  Top
REF 1 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.